Open an account

SpringWorks Therapeutics

SWTX · NASDAQ

Price unavailable right now.

No price history for this range.

About SWTX

Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. The company is headquartered in Stamford, Connecticut and currently employs 368 full-time employees. The firm developed and is commercializing OGSIVEO (nirogacestat) as a Food and Drug Administration (FDA)-approved medicine for adults with desmoid tumors and GOMEKLI (mirdametinib) as an FDA-approved medicine for both adults and children with neurofibromatosis type I associated plexiform neurofibromas (NF1-PN). The company is also advancing a diverse portfolio of novel targeted therapy product candidates for patients with both solid tumors and hematological cancers. Brimarafenib is an investigational oral, small molecule, next-generation RAF dimer inhibitor that the Company is advancing in the clinic. SW-682 is an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluating in Hippo-mutant solid tumors. SW-3431 is an investigational, potentially first-in-class, small molecule activator of Protein Phosphotase 2A (PP2A), complexes.

Employees
368
Headquarters
Stamford, Connecticut
Listed
Sep 13, 2019
Sector
Health Care
Industry
Biotechnology
Website
springworkstx.com

SWTX key statistics

This section is temporarily unavailable. Refresh to try again.

SWTX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 13.9% on average.

  1. Q2 FY23: reported -$1.25 per share against an estimate of -$1.29
  2. Q3 FY23: reported -$1.27 per share against an estimate of -$1.36
  3. Q4 FY23: reported -$1.45 per share against an estimate of -$1.27
  4. Q1 FY24: reported -$1.18 per share against an estimate of -$1.20
  5. Q2 FY24: reported -$0.54 per share against an estimate of -$1.14
  6. Q3 FY24: reported -$0.72 per share against an estimate of -$0.7676
  7. Q4 FY24: reported -$1.04 per share against an estimate of -$0.7191
  8. Q1 FY25: reported -$1.11 per share against an estimate of -$0.8194

SWTX news

  • Press releaseGlobe Newswire

    SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology

  • Press releaseGlobe Newswire

    European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors

  • Press releaseGlobe Newswire

    SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors

  • Press releasePRNewswire

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPOF, PRA, SWTX on Behalf of Shareholders

  • Press releaseBusiness Wire

    SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX

  • Press releasePRNewswire

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PRA, AXL, SWTX, VIGL on Behalf of Shareholders

  • Press releasePRNewswire

    $HAREHOLDER NOTICE: The M&A Class Action Firm Continues To Investigate The Merger - PRA, AXL, SWTX and VIGL

  • Press releasePRNewswire

    STOCKHOLDER ALERT: The M&A Class Action Firm Continues Its Investigation Into The Merger - PRA, KRON, AXL, SWTX

Similar companies

Companies in the same industry as SpringWorks Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.